Assessing Clinical Utility of Pharmacogenetic Testing in the Military Health System
Abstract
Response to medications can differ widely among individual patients. Adverse drug reactions can lead to serious morbidity and mortality. Pharmacogenetic (PGx) testing can predict responses to medications and increased risks of adverse events where the genetic basis is understood. Several published manuscripts suggest positive impacts of systematic preemptive PGx testing. However, few studies have been conducted on PGx implementation in the Military Health System (MHS).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 12, 2023
- Source ID
- 10.1093/milmed/usad254
Entities
People
- Bethelhem Markos
- Cara Olsen
- Clesson E Turner
- David Saunders
- Joya Libbus
- Lydia D Hellwig
- Mark Haigney
- Mauricio De Castro
- Tracey Koehlmoos
Organizations
- Defense Health Agency
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Keesler Air Force Base
- National Human Genome Research Institute
- National Institutes of Health
- Uniformed Services University of the Health Sciences